Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CFDA Plans to Double Drug Review Staff: From 800 to 1,600

publication date: Jan 11, 2018

According to an article in BioCentury, the CFDA plans to double its drug application reviewers from 800 presently to 1,600 by 2020. In 2015, the CFDA employed just 170 reviewers, meaning the agency will increase its reviewing staff by almost 10-fold over a six-year period. The news was disclosed by Ruyi He, MD, Chief Scientist of the CFDA and the Center for Drug Evaluation, who was speaking at the WuXi Global Forum in San Francisco earlier this week. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China